Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
Noa Biran(Hackensack University Medical Center), Andrew Ip, Jaeil Ahn(Georgetown University), Ronaldo C. Go(Hackensack University Medical Center), Shuqi Wang(Georgetown University), Shivam Mathura, Brittany Sinclaire(Hackensack University Medical Center), Urszula Bednarz(Hackensack University Medical Center), Michael Marafelias(Hackensack University Medical Center), Eric Hansen, David S. Siegel(Hackensack University Medical Center), André Goy(Hackensack University Medical Center), Andrew L. Pecora(Hackensack University Medical Center), Ihor S. Sawczuk(Seton Hall University), Lauren Koniaris(Hackensack University Medical Center), Micky Simwenyi(Hackensack University Medical Center), Dániel Varga(Hackensack University Medical Center), Lisa Tank(Hackensack University Medical Center), Aaron A Stein, Valerie Allusson(Hackensack University Medical Center Mountainside), George S Lin(Valley Medical Center), William F Oser(John F. Kennedy Medical Center), Roman Tůma(Bayshore Community Hospital), Joseph Reichman(Riverview Medical Center), Louis Brusco(Raritan Bay Medical Center), Kim Carpenter(Jersey Shore University Medical Center), Eric J. Costanzo(Jersey Shore University Medical Center), Vincent Vivona(Ocean Medical Center), Stuart L. Goldberg
Cited by 295Open Access
Abstract
Related Papers
Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference
Effective treatment of severe COVID-19 patients with tocilizumab
Xiaoling Xu, Mingfeng Han, Tiantian Li et al.|Proceedings of the National Academy of Sciences|2020|2.8k